KR20180096698A - 조합 요법 - Google Patents

조합 요법 Download PDF

Info

Publication number
KR20180096698A
KR20180096698A KR1020187020533A KR20187020533A KR20180096698A KR 20180096698 A KR20180096698 A KR 20180096698A KR 1020187020533 A KR1020187020533 A KR 1020187020533A KR 20187020533 A KR20187020533 A KR 20187020533A KR 20180096698 A KR20180096698 A KR 20180096698A
Authority
KR
South Korea
Prior art keywords
cancer
gemcitabine
benzoxy
phosphate
alaninyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187020533A
Other languages
English (en)
Korean (ko)
Inventor
휴 그리피스
Original Assignee
뉴카나 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2015/054158 external-priority patent/WO2017109444A1/en
Priority claimed from GBGB1609770.1A external-priority patent/GB201609770D0/en
Application filed by 뉴카나 피엘씨 filed Critical 뉴카나 피엘씨
Publication of KR20180096698A publication Critical patent/KR20180096698A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187020533A 2015-12-23 2016-12-21 조합 요법 Ceased KR20180096698A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/GB2015/054158 WO2017109444A1 (en) 2015-12-23 2015-12-23 Combination therapy
GBPCT/GB2015/054158 2015-12-23
GBGB1609770.1A GB201609770D0 (en) 2016-06-03 2016-06-03 Combination therapy
GB1609770.1 2016-06-03
PCT/GB2016/054018 WO2017109486A1 (en) 2015-12-23 2016-12-21 Combination therapy

Publications (1)

Publication Number Publication Date
KR20180096698A true KR20180096698A (ko) 2018-08-29

Family

ID=57681677

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187020533A Ceased KR20180096698A (ko) 2015-12-23 2016-12-21 조합 요법

Country Status (29)

Country Link
US (2) US20190022117A1 (cg-RX-API-DMAC7.html)
EP (2) EP3738595A1 (cg-RX-API-DMAC7.html)
JP (1) JP6898329B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180096698A (cg-RX-API-DMAC7.html)
CN (1) CN108697725A (cg-RX-API-DMAC7.html)
AU (1) AU2016375861B2 (cg-RX-API-DMAC7.html)
CA (1) CA3008749C (cg-RX-API-DMAC7.html)
CY (1) CY1122835T1 (cg-RX-API-DMAC7.html)
DK (1) DK3393478T3 (cg-RX-API-DMAC7.html)
EA (1) EA037459B1 (cg-RX-API-DMAC7.html)
ES (1) ES2778933T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20200423T1 (cg-RX-API-DMAC7.html)
HU (1) HUE050290T2 (cg-RX-API-DMAC7.html)
IL (1) IL260076A (cg-RX-API-DMAC7.html)
LT (1) LT3393478T (cg-RX-API-DMAC7.html)
MA (1) MA51576A (cg-RX-API-DMAC7.html)
MD (1) MD3393478T2 (cg-RX-API-DMAC7.html)
ME (1) ME03677B (cg-RX-API-DMAC7.html)
MX (1) MX383988B (cg-RX-API-DMAC7.html)
MY (1) MY194629A (cg-RX-API-DMAC7.html)
PH (1) PH12018501339A1 (cg-RX-API-DMAC7.html)
PL (1) PL3393478T3 (cg-RX-API-DMAC7.html)
PT (1) PT3393478T (cg-RX-API-DMAC7.html)
RS (1) RS60211B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201805184TA (cg-RX-API-DMAC7.html)
SI (1) SI3393478T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000154T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017109486A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201804155B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013346515B2 (en) 2012-11-16 2017-05-25 NuCana plc Process for preparing nucleoside prodrugs
EA033046B1 (ru) 2014-06-25 2019-08-30 НУКАНА ПиЭлСи Состав, содержащий пролекарство гемцитабина
RS60968B1 (sr) 2014-06-25 2020-11-30 NuCana plc Prolekovi gemcitabina
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
PH12018500691B1 (en) 2015-10-05 2022-08-10 NuCana plc Combination therapy
CA3007347C (en) 2015-12-11 2020-08-04 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
EA201491629A1 (ru) * 2012-08-13 2015-08-31 Регулон, Инк. Способы лечения рака с использованием липоплатина
JP6420247B2 (ja) * 2012-11-13 2018-11-07 ボーイエン セラピューティクス,インコーポレイティド ゲムシタビンプロドラッグ及びその使用
CN107835687A (zh) * 2015-05-14 2018-03-23 努卡那有限公司 癌症治疗
PH12018500691B1 (en) * 2015-10-05 2022-08-10 NuCana plc Combination therapy

Also Published As

Publication number Publication date
US20190022117A1 (en) 2019-01-24
JP2019509253A (ja) 2019-04-04
MX2018007772A (es) 2019-07-04
WO2017109486A1 (en) 2017-06-29
SMT202000154T1 (it) 2020-05-08
HK1255110A1 (en) 2019-08-02
US20230149436A1 (en) 2023-05-18
ME03677B (me) 2020-10-20
EA201891473A1 (ru) 2019-01-31
MA51576A (fr) 2020-11-18
PH12018501339A1 (en) 2019-02-18
ZA201804155B (en) 2021-06-30
LT3393478T (lt) 2020-04-10
DK3393478T3 (da) 2020-03-23
MY194629A (en) 2022-12-07
EP3738595A1 (en) 2020-11-18
CY1122835T1 (el) 2021-05-05
AU2016375861B2 (en) 2021-12-23
MX383988B (es) 2025-03-14
CA3008749C (en) 2024-01-02
MD3393478T2 (ro) 2020-04-30
PL3393478T3 (pl) 2020-07-13
BR112018012956A2 (pt) 2019-01-08
PT3393478T (pt) 2020-03-24
JP6898329B2 (ja) 2021-07-07
CN108697725A (zh) 2018-10-23
CA3008749A1 (en) 2017-06-29
SG11201805184TA (en) 2018-07-30
RS60211B1 (sr) 2020-06-30
HRP20200423T1 (hr) 2020-09-04
SI3393478T1 (sl) 2020-07-31
HUE050290T2 (hu) 2020-11-30
IL260076A (en) 2018-07-31
EP3393478A1 (en) 2018-10-31
ES2778933T3 (es) 2020-08-12
EA037459B1 (ru) 2021-03-30
EP3393478B1 (en) 2020-03-04
AU2016375861A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
KR102566461B1 (ko) 조합 요법
US20220323475A1 (en) Combination therapy for cancer
US20230149436A1 (en) Combination therapy
CN106459129B (zh) 吉西他滨前药
CN111295193A (zh) 组合疗法
HK40038228A (en) Combination therapy
HK1255110B (en) Combination therapy
BR112018012956B1 (pt) Uso de gencitabina-[fenil-(benzóxi-l-alaninil)]-fosfato ou um sal ou solvato farmaceuticamente aceitável do mesmo no tratamento de câncer
NZ743529A (en) Combination therapy
BR112018006880B1 (pt) Uso de gencitabina-[fenil-benzóxi-l-alaninil)]-fosfato ou um sal farmaceuticamente aceitável ou solvato da mesma e carboplatina no tratamento de câncer
NZ624323B2 (en) Methods for treating cancers using oral formulations of cytidine analogs

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180717

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211209

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240109

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240611

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20240109

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I